THE PHARMACOKINETICS OF GS-5816, A PANGENOTYPIC HCV-SPECIFIC NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH SEVERE RENAL IMPAIRMENT

被引：8

作者：

Mogalian, E. ^{[1
]}

Mathias, A. ^{[1
]}

Brainard, D. ^{[2
]}

Shen, G. ^{[3
]}

McNally, J. ^{[2
]}

Sajwani, K. ^{[4
]}

Robson, R. ^{[5
]}

Ries, D. ^{[6
]}

Lasseter, K. ^{[7
]}

Marbury, T. ^{[8
]}

机构：

[1] Gilead Sci Inc, Clin Pharmacol, Foster City, CA 94404 USA

[2] Gilead Sci Inc, Clin Res, Foster City, CA 94404 USA

[3] Gilead Sci Inc, Biostat, Foster City, CA 94404 USA

[4] Gilead Sci Inc, Clin Operat, Foster City, CA 94404 USA

[5] Christchurch Clin Studies Trust Ltd, Christchurch, New Zealand

[6] Prism Res Inc, St Paul, MN USA

[7] Clin Pharmacol Miami Inc, Miami, FL USA

[8] Orlando Clin Res Ctr, Orlando, FL USA

来源：

关键词：

D O I：

10.1016/S0168-8278(15)30915-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0712

引用

页码：S590 / S591

页数：2